Literature DB >> 18255269

The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.

Matthew J Byerly1, Paul A Nakonezny, A John Rush.   

Abstract

Among outpatients with schizophrenia, antipsychotic non-adherence is common, grossly under-detected by patients and their prescribers, and is associated with poor clinical outcomes. Using electronic monitoring (EM) as the reference standard we evaluated the reliability and validity as well as the sensitivity and specificity of a recently developed, brief, pencil-paper, clinician-administered adherence instrument [the Brief Adherence Rating Scale (BARS)] to assess the oral antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. EM and BARS adherence and symptom severity ratings were gathered at baseline and prospectively at 6 monthly visits in 61 participants (n=35 with schizophrenia; n=26 with schizoaffective disorder). A significant positive relationship was found between mean BARS and EM adherence (beta=0.98; rs=0.59, p<0.0001). Cronbach's coefficient alpha revealed very high internal reliability for the BARS (alpha=0.92). A moderate-to-strong degree of test-retest reliability was also found for the BARS (beta ranged from 0.53 to 0.92 and rs ranged from 0.46 to 0.86). Regarding concurrent validity of the BARS, greater mean BARS adherence was significantly related to lower mean PANSS total scores (beta=-0.40; rs=-0.39, p=0.002) and to lower mean Positive symptom sub-scale scores (beta=-0.08, p=.007; rs=-0.28, p=.02). An initial 3-month monitoring period with the BARS also demonstrated good sensitivity (73%) and specificity (74%) in identifying non-adherent outpatients (defined as <70% mean EM adherence). Relative to EM, the BARS appears to provide valid, reliable, sensitive, and specific estimates of antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. The BARS appears to be a promising candidate as a brief adherence assessment instrument for feasible use in community-based settings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18255269     DOI: 10.1016/j.schres.2007.12.470

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  63 in total

Review 1.  Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices.

Authors:  Lizheng Shi; Jinan Liu; Yordanka Koleva; Vivian Fonseca; Anupama Kalsekar; Manjiri Pawaskar
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Self-report measures of medication adherence behavior: recommendations on optimal use.

Authors:  Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen
Journal:  Transl Behav Med       Date:  2015-07-09       Impact factor: 3.046

Review 3.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 4.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

5.  The enduring challenge of antipsychotic non-adherence.

Authors:  T Scott Stroup; Lisa B Dixon
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

6.  Examination of heterogeneity in treatment response to antipsychotic medications.

Authors:  Natalie Bareis; T Scott Stroup
Journal:  Schizophr Res       Date:  2019-08-01       Impact factor: 4.939

7.  Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.

Authors:  Michael J Crawford; Lavanya Thana; Rachel Evans; Alexandra Carne; Lesley O'Connell; Amy Claringbold; Arunan Saravanamuthu; Rebecca Case; Jasna Munjiza; Sandra Jayacodi; Joseph G Reilly; Elizabeth Hughes; Zoe Hoare; Barbara Barrett; Verity C Leeson; Carol Paton; Patrick Keown; Sofia Pappa; Charlotte Green; Thomas Re Barnes
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

8.  PACE--the first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial.

Authors:  Christopher M Williams; Jane Latimer; Christopher G Maher; Andrew J McLachlan; Chris W Cooper; Mark J Hancock; Richard O Day; James H McAuley; Chung-Wei Christine Lin
Journal:  BMC Musculoskelet Disord       Date:  2010-07-23       Impact factor: 2.362

9.  Victimization of patients with severe psychiatric disorders: prevalence, risk factors, protective factors and consequences for mental health. A longitudinal study.

Authors:  Jack J M Dekker; Jan Theunissen; Rien Van; Jaap Peen; Pim Duurkoop; Martijn Kikkert
Journal:  BMC Public Health       Date:  2010-11-10       Impact factor: 3.295

Review 10.  Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis.

Authors:  Lizheng Shi; Jinan Liu; Vivian Fonseca; Philip Walker; Anupama Kalsekar; Manjiri Pawaskar
Journal:  Health Qual Life Outcomes       Date:  2010-09-13       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.